Key information

Title
NOVEL FISH VIRUS
Application number
20180836
Case type
National
Status
Filed
15.06.2018
Effective date
15.06.2018
Publicly available
16.12.2019
Next annual fee due
30.06.2027
Applicant
PatoGen AS (NO)
Owner
PatoGen AS (NO)
Inventor
Håvard Aanes (NO) et al.
Agent
ACAPO ONSAGERS AS (NO)
Granted
09.03.2020
Patent number
344698
Expiry date
15.06.2038

Abstract and drawing


Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content.
The invention relates to a novel fish virus, an isolated nucleic acid having a sequence selected from the group consisting of SEQ ID No 2 and 3, sequences being complementary to SEQ ID NO 2 and 3, and variants thereof being at least 705 % identical thereof. The invention also relates to a method for detection of the nucleic acid, primers, probes, a vector and a host cell, a DNA vaccine, a recombinant protein, a recombinant vaccine, an antibody and a diagnostic kit.

Publications


B1A1
Checking availability of the latest published version...

Documents


Expand Download files (41)
Date
Date Doc. No. Process Case number In/Out Journal description To/from
11.03.2020 16-01 Saksbehandling 20180836 UT PT Registreringsbrev Nasjonal Patent (15) (PT20180836)
28.02.2020 15-03 Saksbehandling 20180836(344698) INN Debetoppgave 27.02.2020 ACAPO AS
28.02.2020 15-02 Saksbehandling 20180836(344698) INN 01-PT Meddelelse om patent (002) ACAPO AS
28.02.2020 15-01 Saksbehandling 20180836(344698) INN Korrespondanse (Hovedbrev inn) ACAPO AS
29.01.2020 14-01 Saksbehandling 20180836 UT PT Meddelelse om patent ACAPO AS
28.11.2019 13-07 Saksbehandling 20180836 INN Krav norsk ACAPO AS
28.11.2019 13-06 Saksbehandling 20180836 INN Krav ren engelsk ACAPO AS
28.11.2019 13-05 Saksbehandling 20180836 INN Krav merket engelsk ACAPO AS
28.11.2019 13-04 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
28.11.2019 13-03 Saksbehandling 20180836 INN Beskrivelse ren ACAPO AS
28.11.2019 13-02 Saksbehandling 20180836 INN Beskrivelse merket ACAPO AS
28.11.2019 13-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
04.11.2019 12-01 Saksbehandling 20180836 UT Realitet patent ACAPO AS
29.07.2019 11-02 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
29.07.2019 11-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
21.06.2019 09-01 Saksbehandling 20180836 UT Generelt brev Patent uten frist ACAPO AS
14.06.2019 10-05 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
14.06.2019 10-04 Saksbehandling 20180836 INN Overdragelsesdokument - Meritxell ACAPO AS
14.06.2019 10-03 Saksbehandling 20180836 INN Overdragelsesdokument - Teresa Garzon ACAPO AS
14.06.2019 10-02 Saksbehandling 20180836 INN Overdragelsesdokument - Cockerill ACAPO AS
14.06.2019 10-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
14.06.2019 08-02 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
14.06.2019 08-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
28.05.2019 07-01 Saksbehandling 20180836 UT Realitet patent ACAPO AS
25.02.2019 06-05 Saksbehandling 20180836 INN Krav ren ACAPO AS
25.02.2019 06-04 Saksbehandling 20180836 INN Krav merket ACAPO AS
25.02.2019 06-03 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
25.02.2019 06-02 Saksbehandling 20180836 INN Beskrivelse merket ACAPO AS
25.02.2019 06-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
08.11.2018 05-02 Saksbehandling 20180836 UT PT_report 10:31:34
08.11.2018 05-01 Saksbehandling 20180836 UT Realitet patent ACAPO AS
05.09.2018 04-03 Saksbehandling 20180836 INN Erklæring Søkers rett til oppfinnelse ACAPO AS
05.09.2018 04-02 Saksbehandling 20180836 INN Fullmakt ACAPO AS
05.09.2018 04-01 Saksbehandling 20180836 INN Korrespondanse (Hovedbrev inn) ACAPO AS
21.06.2018 03-01 Saksbehandling 20180836 UT Formalia 1 ACAPO AS
21.06.2018 02-01 Saksbehandling 20180836 UT Infobrev til oppfinner ACAPO AS
15.06.2018 01-05 Saksbehandling 20180836 INN Hovedbrev ACAPO AS
15.06.2018 01-04 Saksbehandling 20180836 INN fig ACAPO AS
15.06.2018 01-03 Saksbehandling 20180836 INN Beskrivelse ACAPO AS
15.06.2018 01-02 Saksbehandling 20180836 INN Beskrivelse ACAPO AS
15.06.2018 01-01 Saksbehandling 20180836 INN Søknadsskjema Patent ACAPO AS

Description, claims and drawings


Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content. Description
Novel Fish VirusThe present invention relates to use of a novel virus for vaccines and prophylactic treatment for a disease caused by the virus. The invention also relates to nucleic acid sequences, amino acid sequences, primers and primer pairs, probes and methods for diagnostic according to the preamble of the independent patent claimsFish are an increasingly important source of food and income; global annual consumption is projected to rise from 110 million tons in 2010 to more than 200 million tons in 2030. However, the emergence of infectious diseases in aquaculture threatens production and may also impact wild fish populations.During summer 2017 it was discovered particularly high mortality in several cages in a fish farm in Scotland. A novel fish virus was characterized from samples of the fish.The novel virus was isolated in a salmon farm with high losses caused by disease. The virus shows unique characters and 28% similarity to unclassified Fisavirus1, that has previously been identified in Carp (Cyprinus carpio) (Reuter 2016). The sequence of Fisavirus is 8712 NT long and relates to Posavirus (Porcine stool associated virus), and it is assumed that the host of Fisavirus could be the Nematoda phylum (Reuter 2016). Nematodes (Nematoda) belong to the most frequent and the most important parasites of fishes in the freshwater, brackish-water and marine environments throughout the world (Moravec 2007). Small numbers of nematodes often occur in healthy fish, but high numbers cause illness or even death (Roy P. Yanong). Thus it is expected that the novel virus may have a broad range of hosts among fish and shellfish, such as shrimp, carp, tilapia, seabass and salmon, among others.There is therefore a need for a rapid method to identify the virus, and a tool to monitor the production of virus and avoid outbreak. The present invention as described below, identifies the novel virus from fish, and describes methods for identification, detection and vaccine development. Another object is to develop further treatment to treat infected fish.The virus may also be used in challenge methods using a virus according to the invention for testing susceptibility of animals, with the purpose of testing for instance efficacy of a vaccine or functional feed, or resistance towards disease. Further, the virus may be used in breeding programs to obtain animals that are resistant to the virus as defined above.The new virus is isolated from Atlantic salmon.The invention relates to an isolated nucleic acid sequence originating from the virus. The sequence is selected from the group consisting of SEQ ID No 2 and 3 and sequences complementary to any of SEQ ID No 2 and 3, and variants thereof being at least 70% identical.The isolated nucleic acid sequence may further be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 or 3, or any sequences being complementary to SEQ ID No 2 or 3.In another aspect of the invention, it relates to a nucleic acid sequence of at least 10 nucleotides, wherein said sequence hybridizes specifically to a nucleic acid sequence having a sequence selected from the group consisting of. SEQ ID No 4-12, sequences being complementary to SEQ ID No 4-12, and variants being at least 70 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to the variants of SEQ ID NO 4-12. Such a nucleic acid may be used as a primer for instance for PCR or a probe for instance for identification of a nucleic acid sequence or gene. Further, the said nucleotide sequence may be at least 15 or at least 20 nucleotides long.In another aspect the invention provides a primer or probe comprising a sequence selected from the group consisting of SEQ ID NO 4-12, sequences being complementary to SEQ ID NO 4-12, and variants being at least 90 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to the variants of SEQ ID NO 4-12. In some aspects the primer may be 15 nucleotides or 20 nucleotides long.The above said nucleic acid sequence being at least 10 nucleotides long, or the primer or probe, may further be at least 95 %, even more preferred 99% identical with the sequence SEQ ID No 2-12, or any sequences being complementary to SEQ ID No 2-12.According to another aspect of the invention, a method for detection of a virus in a biological sample is provided. The method comprises the following steps:a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,b) subjecting the mixture of a) to a polymerase chain reaction with a primer pair, wherein each primer of said primer pair comprises at least 10 nucleotides and hybridizes to a nucleic acid sequence selected from the group consisting of SEQ ID No 4-12, sequences being complementary to SEQ ID No 4-12, and variants being at least 90 % identical with any of the sequences,c) determining whether the binding of the nucleotide sequences to nucleotide sequences in the biological sample and amplification of the sequence between them have occurred indicating the presence of virus in the sample tested.In a preferred embodiment, the primers of the method above are selected from a group consisting for SEQ ID No 4-12, preferably SEQ ID NO 7-12.In step b) of the method above, the primers may further hybridize to a nucleic acid being at least 95 % or 100 % identical with the sequences SEQ ID No 4-12, or any sequences being complementary to SEQ ID No 4-12.According to another aspect of the invention, another method for detection of a virus in a biological sample is provided. The method comprises the following steps: a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,b) sequencing the mixture of a), andc) comparing the resulting sequence with a sequence selected of the group consisting of SEQ ID No 2 and 3 and sequences being complementary to SEQ ID NO 2 and 3, wherein 70 % identity indicates the presence of virus in the biological sample tested.Further, in step c) of the method above, 80 %, 90%, 95% or 100 % identity may be required to confirm the presence of virus in the biological sample.In a preferred embodiment, the sequencing of the mixture in the method above is performed by a method selected from the group consisting of Next Generation Sequencing, preferably Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent or SOLiD sequencing (Goodwin S, et al., (2016) Coming of age: Ten years of next-generation sequencing technologies. Nature reviews, Genetics, 17, 333-351).The invention also relates to use of a nucleic acid sequence comprising at the least 10 contiguous nucleotides of any of the sequences 2-12, or 10 contiguous nucleotides being complementary of any of the sequences 2-12, for confirming the presence of the virus in a biological sample. In yet another embodiment it is used a nucleic acid sequence having a sequence selected from the group of SEQ ID No 2 and 3 and sequences being complementary to the any of the sequences SEQ ID No 2 and 3.The methods and uses above may be used to confirm that the virus is present in the biological samples, but it may also be used to confirm that the virus is not present in the biological samples. Further, it may be used to monitor a fish population, for instance for disease/sickness control. Information in this regard, desirable with methods for identifying other diseases and/or sicknesses, may be valuable information as to if or when the fish population should be treated. The biological samples to be analysed are preferably from dead fish, but may also be samples removed from live fish without harming the fish.Another aspect of the invention relates to a vector comprising nucleic acid sequences according to the present invention, and host cells comprising said vectors.According to yet another aspect of the invention, DNA vaccines are provided comprising a nucleic acid sequence selected from the group consisting of SEQ ID No. 2 and 3, sequences being complementary to sequences of SEQ ID No 2 and 3, and variants thereof being at least 70% identical with any of the sequences SEQ ID No. 2 and 3 or sequences being complementary to variants of SEQ ID No 2 and 3.The nucleic acid sequence of the DNA vaccine may further be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 and 3, or any sequences being complementary to SEQ ID No 2 and 3.Another aspect of the invention relates to recombinant proteins encoded by a nucleic acid sequence selected from the group consisting of SEQ ID No.2 and 3, and variants thereof being at least 70 %, 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No.2 and 3. In one aspect the amino acid sequence of the recombinant protein is given in SEQ ID No 1.The present invention also provides a recombinant vaccine comprising at least one of the recombinant proteins according to the present invention.The immunogenic composition may further comprise at least one excipient, additive or adjuvant, and may be administrated orally, by immersion or by injection.Furthermore, according to another aspect of the invention, it is provided an antibody that recognises and binds to a recombinant protein according to the present invention. The invention also relates to a diagnostic kit, which may be used to decide whether a sample comes from an organism being infected by the virus according to the invention.Finally, the present invention relates to the use of the nucleic acid sequences having a sequences selected from the group consisting of SEQ ID NO 2 and 3, sequences being complementary to SEQ ID NO 2 and 3, and variants thereof being at least 70 %, 80 %, preferably 90%, more preferably 95 % identical with any of these sequences, for the preparation of DNA vaccine, recombinant vaccine or a live recombinant microorganism.The present invention relates to isolated nucleic acid sequences and variants thereof being at least 70% identical with the isolated nucleic acid sequences. The term "% identity" is to be understood to refer to the percentage of nucleotides that two or more sequences or fragments thereof contains that are the same. The term "at least 70 % identical" thus means that at least 70 % of the nucleotides over the entire sequences which are compared, are identical. A specified percentage of nucleotides can be referred to as e.g. 70% identical, 80% identical, 85% identical, 90% identical, 95% identical, 99% identical or more over a specified region when compared and aligned for maximum correspondence. The skilled person will acknowledge that various means for comparing sequences are available.The term "variants thereof" used in respect of the nucleic acid sequences and recombinant proteins according to the present invention, is to be understood to encompass nucleic acid sequences and recombinant proteins that only differs from the isolated sequences SEQ ID No.1, 2, and 3 by way of some amino acid or nucleotide additions, deletions or alteration that have little effect, if any, on the functional activity of the claimed sequences. The skilled person will acknowledge that modifications of a protein coding nucleotide sequence may be introduced which does not alter the amino acid sequence, e.g. the substitution of a nucleotide resulting in that the triplett affected by the substitution still codes for the same amino acid. Such alterations may be introduced to adapt the nucleic acid sequence to the codons preferably used by a host cell and thus to enhance the expression of a desired recombinant protein. Furthermore, the addition of nucleic acid sequences coding polypeptides which facilitates purification may be added without affecting the activity of the resulting recombinant protein.The skilled person will further acknowledge that also alterations of the nucleic acid sequence resulting in modifications of the amino acid sequence of the recombinant protein it codes may have little, if any, effect on e.g. the proteins' ability to induce protection against the virus if the alteration does not have any impact on the resulting three dimensional structure of the recombinant protein. For example, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a recombinant protein with substantially the same functional activity as the protein encoded by the nucleotide sequence SEQ ID No.2 or 3 and thus to be expected to constitute a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal or C-terminal portions of the protein molecule would also not be expected to alter the functional activity of the protein. Each of the proposed modifications is well within the routine skills in the art, as is determination of retention of biological activity of the encoded products. Therefore, where the terms "nucleic acid sequences of the invention" or "recombinant protein of the invention" are used in either the specification or the claims each will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent protein.Thus, the present invention encompasses recombinant proteins and variants thereof which differ in respect of amino acid substitutions, addition or deletions compared with the protein of SEQ ID No 1, and proteins being encoded by the sequence SEQ ID No.2 or 3. The primers and probes according to the present invention, will hybridize under stringent conditions with the sequence in question. The term “hybridizing under stringent conditions” refers to conditions of high stringency, i.e. in term of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. With “high stringency” conditions, nucleic acid base pairing will occur only between nucleic acids having a high frequency of complementary base sequences. Stringent hybridization conditions are known to the skilled person (see e.g. Green M. R., Sambrook, J., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 4th edition, 2012).The precise conditions for stringent hybridization are typically sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.The term "antigen" when used in connection with the present invention is to be understood to refer to a recombinant protein or fragment thereof according to the invention being able to induce protection against the virus in fish or to be able to bind to an antibody which recognise and bind to the virus. The term "vaccine" as used herein refers to a material that can produce an immune response that blocks the infectivity, either partially or fully, of an infectious agent, which in respect of the present invention is the virus affecting fish such as e.g. salmonids. Thus, when administering the vaccines of the invention to a fish, the fish becomes immunised against the disease caused by the virus. The immunising component of the vaccine may be e.g. DNA as in a DNA vaccine, RNA as in a RNA vaccine, a recombinant protein or fragment thereof according to the present invention, or a live recombinant microorganism. The vaccines may be administered by immersion, orally or by injection.The present invention also provides short nucleotide sequences having a length of at least 10 nucleotides. These sequences may be primers or probes useful in polymerase chain reaction techniques to be used as diagnostic tools. The terms "primer" and "probes" as used herein refers to an oligonucleotide either naturally occurring or produced synthetically which is significantly complementary to a virus target sequence and thus capable of hybridizing to nucleic acid sequences of the present invention. When a primer pair is used, it is generally one forward and one reverse primer, and the sequence between the primers will be multiplied during a PCR. This is well known to a skilled person, and he/she would know which primers constitute a suitable pair. The amplified sequence may be labelled to facilitate detection, e.g. using fluorescent labels on a probe, or other label means well known to the skilled person.FiguresThe invention will now be described in detail with reference to the enclosed Figures, whereFigure 1 shows the cumulated mortality of infected fish during 2017,Figure 2 shows the amino acid sequence encoded by SEQ ID No.3, the amino acid sequence is corresponding to SEQ ID No 1,Figure 3 shows the genomic sequence of the novel virus (PV) corresponding to SEQ ID No.2, Figure 4 shows the genomic sequence of the CDS of the novel virus (PV), corresponding to SEQ ID No. 3,Figure 5 shows the genomic sequence of PV1P corresponding to SEQ ID No.4, Figure 6 shows the genomic sequence of PV2P corresponding to SEQ ID No.5, Figure 7 shows the genomic sequence of PV3P corresponding to SEQ ID No.6, Figure 8 shows the genomic sequence of PV1F corresponding to SEQ ID No.7, Figure 9 shows the genomic sequence of PV2F corresponding to SEQ ID No.8, Figure 10 shows the genomic sequence of PV3F corresponding to SEQ ID No.9, Figure 11 shows the genomic sequence of PV1R corresponding to SEQ ID No.10, Figure 12 shows the genomic sequence of PV2R corresponding to SEQ ID No.11, andFigure 13 shows the genomic sequence of PV3R corresponding to SEQ ID No.12.ExamplesReference throughout the description to "an embodiment" signifies that a particular feature, structure or property specified in connection with an embodiment is included in the least in one embodiment. The expressions "in one embodiment", "in a preferred embodiment" or "in an alternative embodiment" different places in the description does not necessarily point to the same embodiment. Further, the different features, structures or properties may be combined in any suitable way in one or more of the embodiments.Disease outbreakA group of 70000 Atlantic salmon were stocked in sea water October 1st 2016 at a commercial fish farm. Some mortality was observed during stocking, but the mortality was low in the period from March 2017 through June 2017. From June 2017 the mortality increased steadily. In September 2017, the mortality had reached more than 75% (Figure 1).The fish showed symptoms of severe anaemia.Tissue: RNA sequencing and virus detectionOn the day of slaughter, 2 September 2017, samples from gill, heart and kidney were collected from 10 fish, from the outbreak above, and sent to PatoGen for analysis by Real-Time qPCR. The samples were analysed for Paramoeba perurans, Branchiomonas, Piscine Reovirus (PRV), Pancreas Disease Virus (PDV), Paranucleospora theridion, Pravicapsula pseudobranchicola, Salmon gill poxvirus (SGPVD), Tenacibaculum maritimum, Yersinia ruckeri, Pasteurella skyensis, Piscirickettsia salmonis, and Infectious Pancreatic Necrosis Virus (IPNV) (Table 1). Although the gills were particularly affected by many agents, none of the detected agents could explain the observed anaemia and mortality, considering the symptoms and the results of the analysis.np=not performed; nd=no dataNumber of samples analysed (N)=10 except for * where N=1, **N=2, ***N=7Tissue preparation, RNA isolation and analysisRNA was extracted from samples of kidney, heart and gills using RNAeasy Universal kit (Qiagen) on an automated system at the PatoGen AS accredited commercial laboratory. The RNA quality and concentration of the samples were assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies) and the Qubit 3.0 Fluorometer (Thermo Fischer scientific) using the RNA 6000 Pico Kit (Agilent) and the QubitTM RNA HS Assay kit (Thermo Fischer Scientific). Library preparation and RNA sequencing with Ion Torrent S53,2 µg of RNA from one gill sample was used as starting input for the RNA sequencing library preparation. The RNA from the sample was treated with RiboMinus TM Eukaryote Kit v2 (Thermo Fischer Scientific) to remove ribosomal RNA. The rRNA-depleted RNA was fragmented and library was constructed using the Ion Total-RNA Seq Kit v2 (Thermo Fischer Scientific). The library was bar-coded and further quantified with qRT-PCR.Using the Ion Chef and the Ion 520 TM and Ion 530 TM kit Chef (Thermo Fischer Scientific), the library was clonally amplified on Ion Sphere Particles, loaded into one 530 Chip and sequenced on the Ion Torrent S5 (Thermo Fischer Scientific).Description of bioinformatics analysisApproximately five million reads were generated for the RNA sequencing experiment. BAM-files were converted to FASTQ files using SAMTOOLS fastq command, and we applied our in-house pathogen detection pipeline using the reads. Our approach utilizes publicly available research tools, as described in the following.First, reads were first trimmed 25bp in both the 5’ and 3’ end, and short reads (<10 bps) were removed using VSEARCH (https://github.com/torognes/vsearch). Reads mapping to the salmon genome were then removed using Kraken (Wood and Salzberg, 2014), before sequence construction with SPADES using the remaining reads were performed (Bankevich et al., 2012). The resulting scaffold sequences were then tested for complementarity with known sequences using blastn and blastx algorithms against the nucleotide (nt) and Swiss-Prot databases, respectively.The obtained sequence matched partly to members of the Picornaviridae family (Posavirus and Fisavirus).The final genome is 8,713 bps, and divided into the following sections;Bases 1-602; 5’UTR Bases 603-8,585; CDS (2661 aa)Bases 8,586-8,713; 3’UTRReal Time PCRTo validate if the tentative virus, in the following referred to as PV, could be disease causing we designed a RT-PCR-assay in the presumptive polymerase region of the sequence using forward and reverse primers (PV1-F and PV1-R table 4 and 5), and a minor groove binding (MGB) probe (PV1-P) labelled with 6-FAM (table 3). The primers were designed using the software Primer Express 3.0.1 (Thermo Fischer Scientific). Secondary structures and the possibility of primer dimers were tested using the online software IDT OligoAnalyzer 3.1, and the specificity of the primers and the probe were checked using NCBI’s Blastn. The primers and the probe were found not to form secondary structures or primer dimers, nor to hybridize to any other known sequence. The primers and the probe were manufactured by Thermo Fischer Scientific.The RT-PCR assay was performed using TaqMan® Fast Virus 1-Step Master Mix. Amplifications were done on a QuantStudio 5 Real Time PCR systemThermo Fischer Scientific) with the following conditions: 5 min at 50 °C, 20 sec at 95 °C followed by 45 cycles of 95 °C/3 sec and 60 °C/30 seconds.Results of the qPCRTo validate if the tentative virus could be disease causing, 11 fish with clinical symptoms, and 16 fish with no symptoms were tested with the PV1- qPCR assay (Table 2). Extracted total RNA from gill, kidney or heart samples were used in the test.-----" means negative result of detection. The PV1 Real Time assay detected relatively high amounts of the gene sequence the PV assay targeted. There are multiple factors that may have affected the fish, however the overall trends is clear positive, and samples from the gills of all fish having clinical symptoms, were positive with Ct values ranging from 16,2 to 29,8. The gill tissue from fish with no symptoms of disease were in general negative to PV1 by Real Time assay, except for two fish that had Ct values of 35,4 and 37 which show that there are very small amount of virus detected in these fish. This confirms that the virus detected causes the observed symptoms of anaemia.Additional qPCR assaysWe have designed 3 quantitative Real Time TaqMan assays targeting various regions of the genome, as described above for PV1.Virus stabilityThe virus was passed through cell lines as described 10 times, and the virus did not change.Virulence of the virusJuvenile Atlantic salmon were challenged to a suspension of the virus, in freshwater, under standard conditions. High mortality was observed.
Claims
Claims1. An isolated nucleic acid sequence originating from a virus in Atlantic salmon having a sequence selected from the group consisting of SEQ ID No 2 and 3, sequences being complementary to SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical thereof.2. An isolated nucleic acid sequence according to claim 1, characterized in that the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 or 3, or any sequences being complementary to SEQ ID No 2 or 3.3. A primer and/or probe having a sequence selected from the group consisting of SEQ ID NO 4-12, sequences being complementary to SEQ ID NO 4-12, and variants being at least 90 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to variants of SEQ ID NO 4-12.4. A method for detection of a virus in a biological sample, characterized by comprising the following steps:a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,b) subjecting the mixture of a) to a polymerase chain reaction with a pair of primers according to claim 3, andc) determining whether the binding of the primers to nucleotide sequences in the sample and amplification of the sequence between them have occurred indicating the presence of the virus in the sample tested.5. A method for detection of a virus in a biological sample, characterized by comprising the following steps:a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,b) sequencing the mixture of a), andc) comparing the resulting sequence with the sequence selected of the group consisting of SEQ ID No 2 and 3 and sequences being complementary to SEQ ID NO 2 and 3, wherein at least 70 % identity verifies the presence of the virus in the biological sample tested.6. A method according to claim 5, wherein the sequencing is performed by a method selected from the group consisting in Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.7. A method according to 5 or 6, wherein the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 and 3 or sequences being complementary to SEQ ID No 2 and 3.8. Use of a nucleotide sequence comprising at the least 10 contiguous nucleotides of any of the sequences SEQ ID No 2-12, or 10 contiguous nucleotides being complementary of any of the sequences SEQ ID No 2-12, for establishing the existence of virus in a biological sample.9. Use according to claim 8, wherein the nucleic acid sequence has a sequence selected from the group of SEQ ID No 2 and 3, or a sequence being complementary to the any of the sequences SEQ ID No 2 and 3.10. A vector comprising a nucleic acid sequence according to any one of claims 1-2.11. A host cell comprising a vector according to claim 10.12. A DNA-vaccine comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 2 and 3.13. A recombinant protein encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 2 and 3.14. A recombinant protein having an amino acid sequence according to SEQ ID No 1.15. A recombinant vaccine comprising at least one recombinant protein according to claim 13 or 14.16. An antibody specifically recognizing and specifically binding to a recombinant protein according to claim 12 or 13.17. Diagnostic kit comprising at least one primer sequence according to claim 3.Patentkrav1. Isolert nukleinsyresekvens fra et virus i atlanterhavslaks, med en sekvens valgt fra gruppen omfattende SEQ ID No 2 og 3, sekvenser som er komplementære til SEQ ID NO 2 og 3, og varianter av det som er minst 70 % identisk.2. Isolert nukleinsyresekvens i samsvar med krav 1, karakterisert ved at sekvensen er i det minste 80 %, fortrinnsvis 90%, mer foretrukket 95 % identisk med en av sekvensene SEQ ID No 2 eller 3, eller sekvenser som er komplementære til SEQ ID No 2 eller 3.3. Primer og/eller probe med en sekvens valgt fra gruppen omfattende SEQ ID NO 4-12, sekvenser som er komplementære til SEQ ID NO 4-12, og varianter som er i det minste 90 % identisk med en av sekvensene SEQ ID NO 4-12 og sekvenser som er komplementære til varianter av SEQ ID NO 4-12.4. Framgangsmåte for deteksjon av et virus i en biologisk prøve, karakterisert ved å omfatte de følgende trinn:a) forberede en prøve omfattende nukleinsyresekvenser isolert fra den biologiske prøven, for en revers transkripsjonsreaksjon,b) underkaste blandingen av a) for en polymerase kjedereaksjon med et par primere i samsvar med krav 3, ogc) bestemme hvorvidt binding av primerne til nukleotid-sekvenser i prøven og amplifisering av sekvensen mellom dem har foregått, hvilket indikerer tilstedeværelse av viruset i prøven som ble testet.5. Framgangsmåte for deteksjon av et virus i en biologisk prøve, karakterisert ved å omfatte de følgende trinn:a) forberede en prøve omfattende nukleinsyresekvenser isolert fra den biologiske prøven, for en revers transkripsjonsreaksjon,b) sekvensere blandingen i a), ogc) sammenligne den resulterende sekvensen med sekvensen valgt valgt fra gruppen omfattende SEQ ID No 2 og 3 og sekvenser som er komplementære til SEQ ID NO 2 og 3, idet minst 70 % identitet verifiserer nærvær av viruset i den biologiske prøven som ble testet.6. Framgangsmåte i samsvar med krav 5, idet sekvenseringen er utført med en framgangsmåte valgt fra gruppen omfattende Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent og SOLiD sequencing.7. Framgangsmåte i samsvar med krav 5 eller 6, idet sekvensen er i det minste 80%, fortrinnsvis 90%, mer foretrukket 95 % identisk med en av sekvensene SEQ ID No 2 og 3 eller sekvenser som er komplementære til SEQ ID No 2 og 3.8. Bruk av en nukleotidsekvens omfattende i det minste 10 tilstøtende nukleotider fra en av sekvensene SEQ ID No 2-12, eller 10 sammenhengende nukleotider som er komplementære med en av sekvensene SEQ ID No 2-12, for å påvise nærværet av virus i en biologisk prøve.9. Bruk i samsvar med krav 8, idet nukleinsyresekvensen har en sekvens som er valgt fra gruppen av SEQ ID No 2 og 3, eller en sekvens som er komplementær til en av sekvensene SEQ ID No 2 og 3.10. Vektor omfattende en nukleinsyresekvens i samsvar med et av kravene 1-2.11. Vertscelle omfattende en vektor i samsvar med krav 10.12. DNA-vaksine omfattende en nukleinsyresekvens valgt fra gruppen omfattende SEQ ID NO 2 og 3, og varianter av disse som er i det minste 70 % identisk med en av sekvensene SEQ ID NO 2 og 3.13. Rekombinant protein som er kodet for av en nukleinsyresekvens valgt fra gruppen omfattende SEQ ID NO 2 og 3, og varianter av disse som er minst 70 % identisk med en av sekvensene SEQ ID NO 2 og 3.14. Rekombinant protein med en aminosyresekvens i samsvar med SEQ ID No 1.15. Rekombinant vaksine omfattende i det minste et rekombinant protein i samsvar med krav 13 eller 14.16. Antistoff som særlig gjenkjenner og spesifikt binder seg til et rekombinant protein i samsvar med krav 12 eller 13.17. Diagnostisk kit omfattende i det minste en primer sekvens i samsvar med krav 3.
Drawings

Priority


No priority

Patent classes


IPC classesC12N 7/00C12N 15/86A23K 50/80C07K 14/005CPC classesC12N 7/00C12N 15/86A23K 50/80C07K 14/005

Citations


WO 2012066481 A1 (A1)WO 2004045543 A2 (A2)US 2013045873 A1 (A1)

Applicants, owners and inventors


Owners
PatoGen AS
Postboks 548 6001 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)Org. number: 985525331
Inventors
Håvard Aanes
Bertrand Narvesens vei 4 A 0661 OSLO NO (OSLO Municipality, Oslo county)
Kristoffer Alnes Røyset
Slinningsveien 68 6006 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)
Vidar Teis Aspehaug
Fagerliveien 15 6008 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)
Linda Ramsevik Teigene
Dagerskrybba 5 6013 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)
Magnus Andreas Devold
Vassetvegen 67 6030 LANGEVÅG NO (SULA Municipality, Møre og Romsdal county)
David Cockerill
Crioch Cottage PA384DA CUIL BAY, DUROR, APPIN GB
Teresa Garzon
2, Dalnabeich PA371QY NORTH CONNEL GB
Meritxell Diez Padrisa
Marine Harvest Scotland, Stob Ban House, Glen Nevis Business Park PH336RX, FORT WILLIAM, GB

Agent


ACAPO ONSAGERS AS
ACAPO ONSAGERS AS

Org. number: 932214636

Name and address are automatically synchronized with the Brønnøysund Register Centre.

Open in The Brønnøysund Register Centre
Edvard Griegs vei 1 5059 BERGEN NO (BERGEN Municipality, Vestland county)
Org. number: 932214636
Reference: P17266NO00

Status history


Payment history


Oppositions and appeals


No oppositions or appeals

Administrative limitation


No administrative limitation

Liens and licences


No liens or licenses registered

Gazette entries


No Gazette entries foundOnly events from 2024.03.04 and onwards are shown.